Free Trial
NASDAQ:SPRY

ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis

ARS Pharmaceuticals logo
$11.88 -0.07 (-0.54%)
Closing price 03:59 PM Eastern
Extended Trading
$11.88 -0.01 (-0.08%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ARS Pharmaceuticals Stock (NASDAQ:SPRY)

Key Stats

Today's Range
$11.82
$12.26
50-Day Range
$10.18
$14.88
52-Week Range
$7.55
$18.51
Volume
693,551 shs
Average Volume
1.32 million shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00
Consensus Rating
Buy

Company Overview

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Remove Ads

ARS Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

SPRY MarketRank™: 

ARS Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 379th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ARS Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about ARS Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ARS Pharmaceuticals is -23.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ARS Pharmaceuticals is -23.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ARS Pharmaceuticals has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ARS Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    37.04% of the float of ARS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ARS Pharmaceuticals has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ARS Pharmaceuticals has recently increased by 15.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ARS Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    ARS Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    37.04% of the float of ARS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ARS Pharmaceuticals has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ARS Pharmaceuticals has recently increased by 15.29%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ARS Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for ARS Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 7 people have searched for SPRY on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,893,516.00 in company stock.

  • Percentage Held by Insiders

    40.10% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ARS Pharmaceuticals' insider trading history.
Receive SPRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPRY Stock News Headlines

An AI warning from a Wall Street legend
AI is creeping into every aspect of our daily lives… According to billion-dollar fund manager Louis Navellier, it's never been more important to AI-proof your wealth. He lays out three simple steps to take ASAP in his new video.
ARS Pharmaceuticals initiated with an Outperform at Scotiabank
See More Headlines

SPRY Stock Analysis - Frequently Asked Questions

ARS Pharmaceuticals' stock was trading at $10.55 at the beginning of the year. Since then, SPRY shares have increased by 13.9% and is now trading at $12.0150.
View the best growth stocks for 2025 here
.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $2 million.

Top institutional investors of ARS Pharmaceuticals include Deerfield Management Company L.P. Series C (10.82%), Alliancebernstein L.P. (3.99%), Vanguard Group Inc. (3.57%) and Franklin Resources Inc. (2.03%). Insiders that own company stock include Ra Capital Management, LP, Richard E Lowenthal, Sarina Tanimoto, Laura Shawver, Justin Chakma, Brian Dorsey, Eric Karas and Kathleen D Scott.
View institutional ownership trends
.

Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/06/2024
Today
3/14/2025
Next Earnings (Estimated)
3/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SPRY
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$40.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+160.6%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-54,370,000.00
Pretax Margin
-1,912.15%

Debt

Sales & Book Value

Annual Sales
$2.57 million
Price / Cash Flow
N/A
Book Value
$2.40 per share
Price / Book
4.96

Miscellaneous

Free Float
58,214,000
Market Cap
$1.16 billion
Optionable
Optionable
Beta
1.04
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:SPRY) was last updated on 3/14/2025 by MarketBeat.com Staff
From Our Partners